PASSAGE BIO INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
PASSAGE BIO INC. - More news...
PASSAGE BIO INC. - More news...
- Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022
- UPDATE - Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting
- Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting
- Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Passage Bio Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease
- Passage Bio to Participate in Upcoming Investor Conferences
- Passage Bio Provides Update on Strategic Priorities and Extends Cash Runway
- Passage Bio Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease, A Rare Fatal Pediatric Condition
- Passage Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
- Passage Bio to Participate in Upcoming March Investor Conferences
- Passage Bio to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022
- Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium
- Passage Bio to Showcase GM1 Gangliosidosis and Krabbe Clinical Programs at 2022 WORLDSymposium, February 7 – 11
- Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline
- Passage Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
- Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis
- Passage Bio Announces Pipeline Expansion and Clinical Program Update
- Passage Bio Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Passage Bio to Report Third Quarter 2021 Financial Results on November 4, 2021
- Passage Bio to Participate in Upcoming October Conferences
- Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Passage Bio Announces Maxine Gowen, Ph.D., as Chairwoman of the Board of Directors
- Passage Bio to Present at Citi 16th Annual BioPharma Virtual Conference
- Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights
- Passage Bio Mourns the Sudden Passing of Chairman of the Board Tadataka Yamada, M.D.
- Passage Bio to Present at 12th Annual Wedbush PacGrow Healthcare Conference
- Passage Bio to Report Second Quarter 2021 Financial Results on August 5, 2021
- Passage Bio Announces Inducement Award for Newly Appointed Chief Commercial Officer Under Nasdaq Listing Rule 5635(c)(4)
- Passage Bio Announces Key Executive Appointments
